Exposure to rifampicin is reduced by 53% in tuberculosis patients with Diabetes Mellitus

摘要

Background: Tuberculosis is still one of the major infectious diseases today, especially in South East Asia. Rifampicin is the cornerstone of tuberculosis treatment. Lower plasma concentrations of anti TB drugs have been associated with clinical failure and acquired drug resistance. Type 2 diabetes (DM) and tuberculosis (TB) are closely related. Also, diabetes is associated with slower response to TB treatment and with higher mortality. The pharmacokinetic profile of drugs could be altered in diabetic patients. So far, no studies have assessed the phar-macokinetics of rifampicin in tuberculosis patients with diabetes. Therefore, the aim of this study was to compare the pharmacokinet-ics of rifampicin in tuberculosis patients with and without diabetes.Methods: A descriptive pharmacokinetic study was conducted in a cohort of tuberculosis (TB) patients from an outpatient clinic in Jakarta, Indonesia.